New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Check below for free stories on DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:25 EDTRNAProsensa weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
September 17, 2014
14:57 EDTRNAProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
14:56 EDTRNAProsensa commences re-dosing of drisapersen in North America DMD patients
12:32 EDTANACAnacor management to meet with Jefferies
Subscribe for More Information
08:04 EDTPTCTPTC Therapeutics prepares launch of Translarna in Europe
Subscribe for More Information
September 15, 2014
09:59 EDTPTCTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Realty (ARCP) initiated with an Overweight at JPMorgan... Athlon Energy (ATHL) initiated with a Buy at KLR Group... Capital Product (CPLP) initiated with a Buy at Jefferies... Continental Resources (CLR) initiated with a Buy at Canaccord... Costco (COST) initiated with a Buy at Citigroup... Infinera (INFN) initiated with an Outperform at Barrington... NRG Yield (NYLD) initiated with an Outperform at RBC Capital... PTC Therapeutics (PTCT) initiated with a Buy at Deutsche Bank... Power Solutions (PSIX) initiated with an Outperform at Northland... ServiceNow (NOW) initiated with an Outperform at William Blair... Target (TGT) initiated with a Neutral at Citigroup... Team (TISI) initiated with a Neutral at Sidoti... VeriFone (PAY) initiated with a Buy at Monness Crespi... Wal-Mart (WMT) initiated with a Neutral at Citigroup... Whiting Petroleum (WLL) initiated with a Buy at Canaccord... Winnebago (WGO) initiated with an Outperform at BMO Capital.
07:27 EDTSGMOIBC Life Sciences to hold a conference
Subscribe for More Information
07:26 EDTBLUEPiper Jaffray to hold a conference
Subscribe for More Information
05:45 EDTPTCTPTC Therapeutics initiated with a Buy at Deutsche Bank
Target $75.
September 10, 2014
10:00 EDTVTLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:06 EDTSGMOSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
06:03 EDTVTLVital Therapies downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
September 9, 2014
10:10 EDTANACAnacor initiated with an Outperform at Avondale (pre-open)
Target $30.
08:07 EDTPTCTPTC Therapeutics completes enrollment of Phase 3 trial of Translarna
PTC Therapeutics announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna, or ataluren, for patients with nonsense mutation Duchenne muscular dystrophy, or nmDMD. Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this year.
September 8, 2014
08:12 EDTRNAProsensa reports positive results from DEMAND II study of drisapersen
Subscribe for More Information
08:11 EDTVTLVital Therapies announces enrollment in VTI-208 trial 75% complete
As of today, 150 of a targeted 200 subjects have been enrolled in VTI-208, our randomized, controlled Phase 3 clinical trial in alcohol induced liver decompensation. Enrollment rates remain consistent with prior projections, and preliminary results are expected in the first half of 2015. Forty-nine clinical sites are now open in the USA, UK, Spain and Australia, and 38 sites have enrolled at least one subject.
07:07 EDTSGMOSangamo reports positive clinical data of ZFP Therapeutic
Subscribe for More Information
September 5, 2014
07:29 EDTDRTXDurata Therapeutics management to meet with Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use